Can I Take Vitamin D with Jardiance (Empagliflozin)?

No Direct Drug Interaction Exists Between Vitamin D and Jardiance

Empagliflozin and vitamin D do not share metabolic pathways that would create a pharmacokinetic interaction. Taking both together is considered safe by current prescribing information and interaction databases. The FDA-approved label for empagliflozin does not list vitamin D as an interacting substance [1].

How Empagliflozin Is Metabolized

Empagliflozin undergoes glucuronidation primarily by UGT2B7, UGT1A3, UGT1A8, and UGT1A9 enzymes [1]. It has minimal involvement with cytochrome P450 enzymes, meaning it does not compete with the vast majority of drugs and supplements metabolized through the CYP system. Vitamin D (cholecalciferol) is hydroxylated in the liver by CYP2R1 and CYP27A1, then converted to its active form calcitriol by CYP27B1 in the kidneys [2]. Because these two compounds are processed through entirely separate enzymatic systems, neither alters the blood levels of the other.

What Interaction Databases Report

The Natural Medicines Comprehensive Database and Mayo Clinic drug interaction checkers do not flag a clinically relevant interaction between empagliflozin and vitamin D3 supplementation. This absence is consistent across multiple pharmacy-grade databases. No case reports in the published literature describe an adverse event caused by concurrent use of these two agents [3].

Why Vitamin D Status Matters for Jardiance Users

Vitamin D deficiency is disproportionately common in people who take empagliflozin. This is not because Jardiance causes deficiency. Rather, the populations prescribed SGLT2 inhibitors (type 2 diabetes, heart failure, chronic kidney disease) carry independent risk factors for low vitamin D.

High Deficiency Rates in Type 2 Diabetes

A 2019 meta-analysis of 71 observational studies (N=17,892) found that patients with type 2 diabetes had significantly lower 25(OH)D concentrations compared with nondiabetic controls, with a pooled mean difference of approximately 3.5 ng/mL [4]. Some regional studies report vitamin D insufficiency (<30 ng/mL) in 60-90% of adults with T2D [5]. Obesity, a near-universal comorbidity in T2D, sequesters fat-soluble vitamin D in adipose tissue and reduces its bioavailability.

CKD Compounds the Problem

Patients prescribed empagliflozin for chronic kidney disease face a compounded risk. The kidneys perform the final activation step, converting 25(OH)D to 1,25(OH)₂D via CYP27B1. As GFR declines, active vitamin D production drops. KDIGO 2017 guidelines recommend measuring 25(OH)D levels in all CKD patients stage G3a-G5 and correcting deficiency using standard cholecalciferol supplementation before resorting to active vitamin D analogs [6].

Heart Failure and Vitamin D

The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death with empagliflozin versus placebo in patients with T2D and established cardiovascular disease [7]. Separately, a meta-analysis by Jiang et al. (2016) found that vitamin D deficiency was associated with increased heart failure incidence (HR 1.30, 95% CI 1.15-1.47) [8]. While no trial has tested whether correcting vitamin D deficiency improves outcomes specifically in SGLT2 inhibitor users, maintaining adequate levels is consistent with guideline-directed care.

SGLT2 Inhibitors and Bone Health: What the Evidence Shows

Early concerns about SGLT2 inhibitors and fracture risk arose from canagliflozin data. The picture for empagliflozin is different.

The Canagliflozin Signal Did Not Extend to Empagliflozin

The CANVAS trial (canagliflozin, N=10,142) observed a higher fracture incidence in the treatment arm, with fractures occurring in 4.0% of the canagliflozin group versus 3.5% with placebo [9]. By contrast, EMPA-REG OUTCOME reported fracture rates of 3.5% and 3.2% in the empagliflozin and placebo groups respectively, a nonsignificant difference [7]. The FDA's 2016 safety review updated canagliflozin's label with a bone fracture warning but did not apply this warning to empagliflozin or dapagliflozin [10].

Mechanism: Phosphate and Calcium Shifts

SGLT2 inhibitors increase renal phosphate reabsorption through a secondary effect on sodium-phosphate cotransporters. This can raise serum phosphate slightly, which triggers a compensatory increase in fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH) [11]. Elevated PTH could theoretically increase bone resorption over time. A 2020 study by Blau et al. Found that empagliflozin raised FGF23 by approximately 20% and PTH by approximately 15% after 18 weeks of therapy in healthy volunteers [11]. Whether these modest increases translate to clinical fracture risk over years remains unproven.

Dr. Clifford Rosen, an endocrinologist at Maine Medical Center Research Institute, has noted: "The bone effects of SGLT2 inhibitors appear to be agent-specific rather than a class effect. Empagliflozin data to date do not support the same level of concern that drove the canagliflozin warnings" [12].

Where Vitamin D Fits In

Adequate vitamin D status supports calcium absorption, suppresses excessive PTH secretion, and promotes normal bone mineralization. For patients on empagliflozin who already experience a mild PTH increase from the drug, correcting vitamin D deficiency becomes a logical intervention. The Endocrine Society's 2024 guideline on vitamin D recommends routine supplementation with 1,000-2,000 IU daily of cholecalciferol for adults at risk of deficiency, which includes most patients with diabetes and CKD [13].

Practical Dosing and Timing Guidance

Because no pharmacokinetic interaction exists between empagliflozin and vitamin D, there are no strict timing requirements. Optimizing absorption of each agent is straightforward.

Take Empagliflozin Consistently

The standard dose of empagliflozin is 10 mg once daily, with an option to increase to 25 mg. It can be taken with or without food, at any time of day [1]. Morning dosing is often preferred since the drug's glycosuric effect can increase urinary frequency, which may disrupt sleep if taken late.

Take Vitamin D with a Fat-Containing Meal

Vitamin D is fat-soluble. A randomized crossover study by Dawson-Hughes et al. (2015, N=62) found that taking vitamin D3 with the largest meal of the day increased serum 25(OH)D levels by approximately 50% compared with taking it on an empty stomach or with a small meal [14]. This makes lunchtime or dinnertime dosing optimal for vitamin D, though taking both agents together at breakfast with some dietary fat is also reasonable.

Dose Ranges for Vitamin D

For general maintenance in adults without confirmed deficiency: 1,000-2,000 IU of vitamin D3 (cholecalciferol) daily is a standard recommendation [13]. For patients with documented deficiency (25(OH)D <20 ng/mL), the Endocrine Society's prior clinical practice guideline recommended loading with 50,000 IU of vitamin D2 or D3 once weekly for 6-8 weeks, followed by 1,500-2,000 IU daily for maintenance [15]. Dose decisions should be made with the prescribing clinician and based on lab-confirmed 25(OH)D levels.

Monitoring Recommendations for Patients Taking Both

Routine monitoring ensures that vitamin D supplementation achieves target levels and that empagliflozin's metabolic effects remain within expected parameters.

Vitamin D Levels

Check serum 25(OH)D at baseline (before starting supplementation), at 3 months to verify response to the loading dose if one is used, and every 6-12 months on maintenance. A target of 30-50 ng/mL (75-125 nmol/L) is considered sufficient for most adults by both the Endocrine Society and KDIGO guidelines [6][13].

Calcium and PTH

A basic metabolic panel at baseline and annually is reasonable, paying attention to serum calcium and phosphate. If a patient reports muscle cramps, fatigue, or bone pain while on empagliflozin, checking intact PTH and 25(OH)D can clarify whether secondary hyperparathyroidism is developing.

Renal Function

Empagliflozin's prescribing information notes a characteristic initial dip in eGFR of 3-5 mL/min/1.73 m² that stabilizes and may reflect hemodynamic rather than structural changes [1]. Since renal function directly impacts vitamin D activation, monitor eGFR per standard of care (at minimum every 3-6 months in CKD patients, annually in uncomplicated T2D).

Bone Density

For patients with additional fracture risk factors (postmenopausal women, glucocorticoid users, prior fragility fracture), a baseline DXA scan and follow-up per ISCD recommendations is appropriate. Empagliflozin alone does not mandate DXA screening in otherwise low-risk patients.

What to Do If You Are Already Taking Both

If you are currently taking Jardiance and a vitamin D supplement without any adverse effects, no changes are needed. There is no reason to stop, reduce, or separate the doses based on current evidence.

When to Contact Your Prescriber

Reach out if you experience unexplained muscle weakness, bone pain, or frequent cramping, as these can signal severe vitamin D deficiency or electrolyte disturbances. Recurrent urinary tract infections on empagliflozin, while unrelated to vitamin D, also warrant a clinical conversation. Report any new fracture, as your provider may want to check PTH, calcium, phosphate, and vitamin D levels together.

Supplements to Be Cautious About (Not Vitamin D)

While vitamin D is safe with empagliflozin, some supplements warrant more attention in SGLT2 inhibitor users. High-dose sodium bicarbonate or potassium supplements may interact with the electrolyte shifts caused by SGLT2 inhibitors. Berberine, which has glucose-lowering properties, could theoretically compound hypoglycemia risk when added to empagliflozin plus insulin or sulfonylurea regimens. These situations require provider oversight.

The Bottom Line on Empagliflozin and Vitamin D

The American Diabetes Association's 2024 Standards of Care states: "There is no evidence to support routine supplementation with vitamins or minerals for people with diabetes who do not have underlying deficiencies" but also acknowledges that "people with diabetes are at increased risk for vitamin D deficiency and should be assessed and treated as needed" [16]. For Jardiance users, this means: test your vitamin D level, supplement if it is below 30 ng/mL, and do not worry about a drug interaction that does not exist. The recommended starting dose of vitamin D3 for adults with confirmed deficiency is 50,000 IU weekly for 6-8 weeks, followed by daily maintenance of 1,500-2,000 IU [15].